Neuroprotective Effects of Vitamin D Supplementation on Outcomes in Traumatic Brain Injury: A Systematic Review and Meta-Analysis

Farzan Fahim[1,2*@], Fatemeh Vosoughian[1,3@], Mahdi Mehmandoost[1,3], Hengameh Yousefi[1], Amirmohammad Bahri[1], Khatere Mokhtari[1], Tohid Emami-Meybodi[1], Iman Sarmadi[1], Amirhossein Zare[1], Shahin Naghizadeh[1], Shideh Moftakhari Hajimirzaei[1], Sayeh Oveisi[1], Alireza Zali[1]

@= Co-First Author

*= Corresponding Author

1. Functional Neurosurgery Research Center, Research Institute of Functional Neurosurgery, Shohada Tajrish Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2. Neurosurgery resident, Functional Neurosurgery Research Center, Shohada-E-Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3. Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

* Corresponding Author

Address: Shohadaye Tajrish Hospital, Tehran Province, Tehran, Shahrdari St.

Phone: 021 2274 9201

E-mail: Farzn.fahim@gmail.com

Affiliation:

1. Functional Neurosurgery Research Center, Research Institute of Functional Neurosurgery, Shohada Tajrish Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2. Neurosurgery resident, Functional Neurosurgery Research Center, Shohada-E-Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract

Background:

Traumatic brain injury (TBI) remains a leading cause of morbidity and mortality worldwide, with secondary brain damage driven by inflammation and oxidative stress. Vitamin D is increasingly recognized for potential neuroprotective effects in TBI, while data regarding vitamin E remain limited.

Objective:

To systematically review and meta-analyze the effects of vitamin D supplementation, and qualitatively review evidence for vitamin E, on clinical and functional outcomes after moderate to severe TBI.

Methods:

A comprehensive search was carried out in PubMed, Scopus, Embase, Web of Science, and Google Scholar up to January 2025. Studies reporting on vitamin D or E supplementation in clinical TBI were eligible. Risk of bias was assessed using JBI checklists. A meta-analysis of randomized controlled trials reporting pre- and post-treatment GCS scores following vitamin D supplementation was performed with a fixed-effect model.

Results:

From 4,546 records, nine clinical studies met criteria; three RCTs on vitamin D (n=151 patients) were included in the meta-analysis, which found that vitamin D supplementation significantly improved GCS scores versus controls (SMD = 1.02, 95% CI: 0.68–1.36, $p < 0.0001$; $I^2 = 0\%$). Narrative analysis suggested that vitamin D may improve functional outcomes, reduce inflammatory biomarkers, and lower mortality in select studies. Evidence for vitamin E in TBI is currently limited to a small number of heterogeneous studies, with early data suggesting possible benefits for acute recovery and oxidative stress reduction, but insufficient for quantitative synthesis.

Conclusion:

Vitamin D supplementation may confer short-term improvement in neurological and functional outcomes following moderate to severe TBI. Existing evidence for vitamin E is insufficient to support robust conclusions. Larger, rigorously designed RCTs—particularly for vitamin E—are required to clarify effectiveness, optimal dosing, and long-term outcomes.

Keywords: traumatic brain injury, vitamin D, vitamin E, neuroprotection, systematic review, meta-analysis

Introduction

Traumatic brain injury (TBI) is a major public health concern and remains one of the leading causes of morbidity, mortality, and long-term disability worldwide, affecting nearly 69 million people annually, particularly in low- and middle-income countries (1, 2). The primary mechanical impact is followed by complex secondary injury cascades, characterized by neuroinflammation, oxidative stress, and disruption of blood–brain barrier function—all of which contribute to further neuronal loss and neurological deterioration (3-5). Severity assessment and monitoring of prognosis in TBI are typically performed using the Glasgow Coma Scale (GCS), a widely used tool for both clinical care and research (3).

A growing body of evidence highlights the pivotal roles of inflammatory cytokines and oxidative stress markers—including TNF-α, IL-1β, and IL-6—in determining the severity and outcomes of TBI (6, 7). Despite advances in acute care, options for modulating secondary brain injury and improving patient prognosis remain limited, driving interest in novel therapeutic strategies (8, 9).

Among potential interventions, antioxidant vitamins have gained considerable research attention. Vitamin D, beyond its classical roles in calcium homeostasis, has demonstrated immunomodulatory, anti-inflammatory, and neuroprotective effects in both pre-clinical and clinical studies (10-12). Animal studies indicate that vitamin D supplementation can attenuate cerebral edema, lower oxidative damage, and improve neuronal recovery after TBI (13, 14). Human studies further suggest that vitamin D deficiency is common after TBI, and lower serum vitamin D levels may be associated with increased risk of unfavorable outcomes (15-17). Early phase clinical trials have shown that vitamin D supplementation improves neurological function, reduces inflammatory markers, and may decrease duration of mechanical ventilation and ICU stay in patients with moderate to severe TBI (18-22), although methodological heterogeneity and small sample sizes limit definitive conclusions.

Vitamin E, a fat-soluble antioxidant, is another candidate neuroprotectant investigated mostly in animal models, where it has been shown to reduce lipid peroxidation and improve functional and cognitive outcomes after TBI (15, 23). However, clinical evidence for vitamin E supplementation in TBI remains sparse and heterogeneous, mostly limited to small-scale studies and those employing combination antioxidant regimens (24, 25). A few randomized trials suggest vitamin E may reduce acute oxidative stress and possibly mortality, but the overall quality and consistency of available human data are low (24, 25).

Despite these promising findings, major gaps persist in the literature. Most studies are limited by small sample sizes, lack of standardization in dosing and timing of supplementation, and inadequate reporting of long-term and patient-centered outcomes. Notably, while there is more robust data for vitamin D, evidence for clinical efficacy of vitamin E remains insufficient for meta-analytic synthesis (24, 25).

However, despite encouraging preliminary evidence, robust data from large-scale randomized controlled trials are still lacking. Critical questions remain regarding optimal dosing, timing of supplementation, ideal target populations, long-term functional outcomes, and the comparative efficacy of vitamin D versus vitamin E in TBI. Addressing these important gaps is essential for developing clear, evidence-based clinical recommendations.

Therefore, the present systematic review and meta-analysis aims to (i) quantitatively evaluate the effects of vitamin D supplementation on neurological and clinical outcomes in TBI patients, and (ii) provide a qualitative synthesis of current evidence for vitamin E supplementation. By identifying strengths, limitations, and future research directions, this study seeks to clarify the therapeutic potential of these antioxidants in the management of TBI.

Methods

Study Design and Registration

This systematic review and meta-analysis were conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. The study protocol was prepared a priori and registered in PROSPERO (Registration ID: 1088575)**.**

Information Sources and Search Strategy

A comprehensive search was performed in PubMed, Scopus, Embase, Web of Science, and Google Scholar, covering records from database inception until January 31, 2025. The search strategy combined Medical Subject Headings (MeSH) and relevant free-text keywords related to vitamin D, vitamin E, traumatic brain injury (TBI), prognosis, functional recovery, and management. The full search strategy for each database is available in Supplementary Table S1. In addition, the reference lists of all included articles and relevant reviews were screened to identify further eligible studies.

Eligibility Criteria

Studies were included if they:

- Enrolled human participants;

- Investigated the effects of vitamin D and/or vitamin E supplementation (including relevant MeSH terms);
- Reported clinical or functional outcomes for adult TBI patients (such as Glasgow Coma Scale [GCS], Glasgow Outcome Scale [GOS/GOS-E], mortality, ICU/hospital stay, or inflammatory/oxidative biomarkers);
- Were published as English-language, full-text original articles.

Studies were excluded if they:

- Were animal or in vitro investigations, case reports, conference abstracts, reviews, meta-analyses, protocols, or editorials;
- Focused exclusively on other vitamins without separate data for vitamin D or E;
- Lacked extractable or relevant outcome data.

Study Selection

Duplicate records were removed using EndNote, and the remaining unique articles were imported into Rayyan for title and abstract screening by two independent reviewers. Full texts of potentially eligible studies were then retrieved and assessed according to the inclusion and exclusion criteria. Discrepancies at any stage were resolved by consensus or, if necessary, by consultation with a third reviewer. The study selection process is illustrated in the PRISMA flow diagram (Figure 1).

Data Extraction

Two reviewers independently extracted data using a standardized, pilot-tested data extraction form. The following variables were collected: first author, year, country, study design, sample size, patient demographics (age, sex, TBI severity), intervention details (supplement type, dose, route, duration), comparator(s), relevant clinical outcomes (GCS, GOS/GOS-E, mortality, hospital and ICU stay, mechanical ventilation duration, biomarkers, adverse events), follow-up, funding sources, and reported conflicts of interest. Any discrepancies in data extraction were resolved through discussion or, if necessary, adjudication by a third reviewer.

Risk of Bias Assessment

Each included study was independently assessed for risk of bias by two reviewers using the appropriate Joanna Briggs Institute (JBI) Critical Appraisal Checklist: the JBI checklist for randomized controlled trials for RCTs and the JBI checklist for cohort studies for cohort designs. Disagreements were resolved

Study	*Num of positive answers*	*Num of negative answers*	*Num of partial/unclear answers*	*Final status*
		Randomized control trial studies		
Sharma et al. 2020	12	-	1	Low
Razmkon et al. 2011	7	2	4	Low
Arabi et al. 2020	5	4	2	Moderate
Aminmansour et al. 2012	10	1	2	Low
Zhang 2018	8	-	5	Low
Masbough et al. 2024	8	1	4	Low
Shafiei et al. 2022	11	-	2	Low
		Cohort studies		
Lee et al. 2019	8	-	3	Low
Guan et al. 2017	9	1	1	Low

through consensus or a third reviewer. No study was excluded based on high risk of bias. The risk of bias assessments are summarized in Table 1.

The risk of bias assessment JBI Critical Appraisal checklists

Data Synthesis and Statistical Analysis

A quantitative meta-analysis was performed for randomized controlled trials (RCTs) that reported pre- and post-intervention GCS scores in vitamin D and control groups. Standardized mean differences (SMD) with 95% confidence intervals (CIs) were calculated. Given the low degree of observed heterogeneity ($I^2 < 25\%$), a fixed-effect model was utilized. Restricted maximum likelihood (REML) estimation and inverse variance weighting were used to compute summary estimates. Heterogeneity was further examined using Cochran's Q test and the I^2 statistic.

Robustness of findings was evaluated by leave-one-out sensitivity analyses. Publication bias was assessed through funnel plot inspection and Egger's regression test. Where data permitted, meta-regression was conducted to assess the influence of age and sex on outcome effect sizes.

All statistical analyses were performed using R (version 4.4.2) with the "meta" and "metafor" packages. For vitamin E supplementation, due to insufficient and heterogeneous evidence, only a qualitative synthesis was conducted.

Outcomes

Primary outcome:

- Change in Glasgow Coma Scale (GCS) following vitamin D or E supplementation.

Secondary outcomes:

- Glasgow Outcome Scale (GOS or GOS-E);
- Mortality;

- Duration of ICU stay, hospital stay, and mechanical ventilation;
- Inflammatory and oxidative stress biomarkers;
- Safety and adverse effects.

Ethics

No ethics approval was required for this systematic review and meta-analysis as only previously published, de-identified data were used.

esults

Study Selection

A total of 4,546 records were identified through database searching. After removal of 1,265 duplicates, 3,281 unique articles were screened by title and abstract using Rayyan. Of these, 28 articles were assessed in full text, and nine studies were included in the final analysis (Figure 1).

Study Characteristics

Nine studies, including six randomized controlled trials and three cohort studies, were published between 2011 and 2024. Sample sizes ranged from 35 to 497 participants. Most studies assessed vitamin D supplementation (oral or intramuscular, with doses ranging from 50,000 to 300,000 IU), while two studies examined vitamin E (intramuscular or intravenous). TBI severity ranged from moderate to severe (admission GCS scores 3–12). Participants were predominantly male (approximately 70–80%), with ages primarily between 30 and 50 years. Full study details are provided in Table 1.

Risk of Bias

The Joanna Briggs Institute (JBI) Critical Appraisal checklists showed most studies to be at low risk of bias, with two studies assessed as moderate due to incomplete blinding or outcome reporting (Table 1).

Quantitative Synthesis (Meta-Analysis)

Three randomized controlled trials (18, 21, 22) (n=151; intervention: 78, control: 73) reported change in Glasgow Coma Scale (GCS) and were included in the meta-analysis. The pooled standardized mean difference (SMD) for GCS improvement with vitamin D versus control was 1.02 (95% CI: 0.68 to 1.36, $p < 0.0001$), favoring vitamin D. Heterogeneity was negligible ($Q = 1.93$, $I^2 = 0\%$, $\tau^2 < 0.0001$). Leave-one-out sensitivity analysis confirmed result stability. No publication bias was detected (Egger's test $t = 0.50$, $p = 0.71$; funnel plot in Supplementary Figure S2). Meta-regression found no significant effect of age (estimate = 0.021, $p = 0.701$) or female proportion (estimate = 16.319, $p = 0.178$) on treatment outcome **(Table 2, Supplementary Figure S1).**

Functional and Clinical Outcomes

Glasgow Outcome Scale (GOS/GOS-E):

Vitamin D-sufficient patients demonstrated higher rates of favorable GOS at 3 and 6 months post-TBI (17), and Lee et al. (19) observed more patients achieving GOS-E ≥6 in the supplemented group at both timepoints. Masbough et al. (20) found that vitamin D increased odds of favorable GOS-E at three months ($P = 0.017$). In Razmkon et al. (24), vitamin E led to higher GOS at discharge ($P = 0.04$); differences faded by later follow-up.

Mortality:

Lower mortality was observed in the vitamin E group in Razmkon et al. (24) ($P = 0.04$), and Shafiei et al. (21) reported a lower (but not statistically significant) mortality with vitamin D. Adjunctive vitamin D with progesterone decreased mortality compared to progesterone alone or placebo (18).

Secondary Outcomes

Mechanical Ventilation and ICU/Hospital Stay:

Vitamin D significantly reduced mechanical ventilation duration (Sharma et al.: 6.19 ± 1.64 vs. 9.07 ± 2.18 days, $P < 0.001$ [21]; Guan et al.: 0.7 ± 3.2 vs. 2.9 ± 6.6 days, $P = 0.01$ (17)). Shafiei et al. (21) and Masbough et al. (20) found no significant difference in ventilation or hospital/ICU stay.

Readmission and Complications:

Vitamin D-sufficient patients experienced lower 30-day readmission (9.5% vs. 13.7%) and hospital-acquired pneumonia (5.0% vs. 13.6%) (17).

Inflammatory and Oxidative Biomarkers:

Vitamin D reduced IL-6, TNF-α, and IL-2, and increased IFN-γ in Sharma et al (22). Masbough et al. (20) noted a significant reduction in neutrophil-to-lymphocyte ratio (NLR). Vitamin E (Zhang et al. (25)) reduced markers of oxidative stress (NTF-κB, OH□, O□□, MDA, AOPP) and nerve injury (NSE, S100B), with increased antioxidant enzymes (SOD, GPx, CAT).



Figure 1. *PRISMA Flow chart*

Author	**Jian Guan**	**Swapnil Sharma**	**Ali Razmkon**
Year	2017	2020	2011
Type of	Prospective study	Double□Blind Randomized Clinical Trial	double-blind,

Table 2. *Characteristics of Included Studies*

the study			placebo-controlled trial.
Included in Meta-analysis		*	
doi	doi:10.3171/2017.2.jns163037	https://doi.org/10.1007/s40261-020-00896-5	10.1227/neu.0b013e3182279a8f
Human (Number of each group, sex, age)	Total N=497 neurosurgery patients (12.1% caused by trauma) Deficient vit D (12- 20 ng/ml): n=182 (F=77, age M=49.5) Traumatic patients: n=24 (13.2%) Sufficient vit D: n=315 (F=148, age M=58) Traumatic patients: n=36 (11.4%) Severely Deficient vit D (less than 12 ng/ml): n= 59 (F=30, age M=48.9) Traumatic patients: n=12 (20.3%)	N=35 F=28.6%, M=71.4% Age=16-65, Mean age =36.4 y Treatment, n=20 Placebo, n=15	Total N=100 F=17 M= 83 Mean age = 31.6 y (16-83) Group A (Low-Dose Vitamin C), n=26 Group B (High-Dose Vitamin C), n=23 Group C (Vitamin E), n=24 mean age: 36.8 (16-73) F=4 M=20 Group D (Placebo), n=27
based GCS	Not mentioned	Mean pre-GCS: Case=7.09 ± 2.21 Control=6.28± 2.36 First day means GCS: Case:7.00 ± 2.14 Control: 5.66 ± 1.82	Admission GCS mean Total= 6.3 Group C (Vit E) = 6.5
operation/ non-operation, details	103 (56.6%) deficient patients and 200 (63.5%) sufficient patients had surgery during NCCU stay.	62.8% of patients underwent surgery	All of the patients received intracranial pressure management.
Severity of Trauma (GCS)	At the 3-month follow-up, 34.6% (N=63) of deficient and 25.1% (N=79) of sufficient groups had lower GOS score (1-3). At the 3-month follow-up, 65.4% (N=119) of deficient and 74.9% (N=236) of sufficient groups had higher GOS scores (4-5).	Seventh day means GCS. Treatment=12.63 ± 1.42 Placebo=8.72 ± 1.84	Not mentioned
Treatment (Dose, taper, placebo) Vitamin E, D	Those who were found to be vitamin D deficient were treated with 50,000 U of ergocalciferol orally or via feeding tube weekly.	The treatment group regimen consists of a 120,000 IU single dose of vitamin D, and the control group regimen includes 8 mg of saccharide as a placebo.	Group A, low-dose vitamin C (500 mg/d IV) for 7 days; Group B, high-dose vitamin C (10 g IV on the first [admission] day and repeated on the fourth day, followed by vitamin C 4 g/d IV for the remaining 3 days); Group C, vitamin E (400 IU/d IM) for 7 days; Group D, placebo
The duration of treatment and follow up	Vitamin D treatment continued during the hospital stay. 3 months of follow-up visits in the clinic	Single-dose treatment, and follow-up after 7 days of treatment.	Treatment for 7 days and follow-up at 2 months and 6 months after discharge.
Findings Effects on prognosis and Outcomes and efficacy 1. In the treatment interv 2. follow up X.1) Results of interventional group X.2) Results of control group	1.2) A sufficient group had a lower admission rate after 30 days of discharge (9.5% vs 13.7%) 1.1) Deficient group were likely to have lower GOS scores (1-3) than sufficient group (34.6% vs 25.1%). 2.1) Severely deficient patients had a higher rate of hospital pneumonia than other patients (13.6% vs 5.0%). 2.1) At 3-month follow-up, Low GOS Score group had been more likely to be vitamin d deficient (44.5% vs33.5%), staying longer in the NCCU (5.3±6.5 vs 3.2±4.1 days) and overall hospital stay (9.1±10.5 vs 5.7±5.5 days), longer dependent on mechanical ventilation(2.9±6.6vs0.7±3.2 days), developing urinary tract infection (12%5.1%)or pneumonia(13.4%vs3.1%) Overall, the study suggests that patients admitted to the NCCU without vitamin D deficiency were more than 1.7 times more likely to achieve a GOS score of 4 or 5 (moderate or low disability) than those who were deficient in vitamin D.	2.1) Seven days after admission, the GCS score elevated by about 3.86 units while decreasing by 0.19 units in the control group. The length of mechanical ventilation and ICU stay was lower in the treatment group (6.19 vs 9.07 days). The GOSE score was higher in the vitamin D group. The pre-intervention vitamin D level in the case group was 18.30, which rose to 39.15 post-intervention by day 7. 2.2) The vitamin D level in the control group was 15.15 before the intervention and reached 27.30 by day 7 after the intervention.	1.1) The vitamin E group had a lower mortality than other groups(p=0.04). 1.2) Length of hospital stay in the placebo group was a little more than the other groups(p=0.08). 2.1) The GOS scores and functional outcomes at discharge and follow-up were significantly better for the vitamin E group patients (P=.04) The significant impact of vitamin E is strongest at discharge, and that the difference decreases at 2 months and decreases further at 6 months of follow-up. The number of patients in a vegetative state (GOS 2) was higher in the vitamin E group.
ESR/CRP/Albmin	None.	Diminished levels of Cytokines such as IL-6, TNF-α, IL-2, and enhanced levels of IFN-γ were noted in the vitamin D group, contrary to the placebo.	Not mentioned
Limitations	Single institution Weak to detect subtle GOS Score in different groups, differences in neurological condition of patients, disability in assessing one-third of patients' GOS Score at the 3-	Small sample size, dominant male patients, short-term follow-up	The authors claimed to have chosen an imprecise secondary oxidative index of the brain injury. The perilesional edema may be affected by oxygenation, vascular sufficiency, and other uncontrollable factors. They also mentioned the lack of

	month follow-up not evaluating the vitamin D level after discharge. They suggest that future research would be improved by including measurements of vitamin D levels at follow-up after the patients have left the hospital. not blinding the assessment of the GOS Score and vitamin D level		advanced monitoring methods (except the intraventricular intracranial pressure monitoring). Small sample size

Seyed Mostafa Arabi	**Jong Min Lee1**	**Bahram Aminmansour**	**Cheng Zhang**
2020	2019	2012	2018
randomized control trial	Retrospective study	randomized clinical trial	RCT
	*	*	
10.1186/s13063-020-04622-6	10.1016/j.wneu.2019.02.244	10.4103/2277-9175.100176	10.4103/2221-6189.233014
N=74 Age=18-65	N=345 Control, n=64 Age=55.91y, Male=53 Supplement, n=180 Age=56.76y, Male=132	N=60 Placebo, n=20, male =12 (60%) GCS mean= 6.3 ±0.88, Progesterone, n=20 male=16 (80%) GCS mean =6.31 ± 0.87 Progesterone-vitamin D, n=20 male=16 (80%) GCS mean =6 ± 0.88	N: 84 intervention group:42 F= 14 M=28 Age M= 25 to 49 years control group:42 F= 13 M=29 Age M= 25 to 49 years
(GCS 7–8 and 8–9)	Control group GCS=12.36 Supplement group GCS=13.14	Progesterone=6.3 Progesterone + vit D=6 Placebo=6.3	GCS= 3-12 points
Not mentioned	Not mentioned	45% of placebo patients, 40% of progesterone +vit D patients, 30% of progesterone patients had surgical procedure.	Not mentioned
Study protocol and results have not been published	GOS score Control=6.81 Supplement=7.16	Placebo = 9.16 ± 1.11, Progesterone =10.25± 1.34, Progesterone-vitamin D= 11.27 ± 2.27	Not mentioned
The experimental group received 100,000 IU of vitamin D as an oral drop, and the control group 1000 IU of vitamin D as a placebo daily for 5 days.	If a patient had a vitamin D deficiency (less than 30 ng/mL), Cholecalciferol was immediately injected at 100,000 IU intramuscularly; If oral medication were possible on the day following intramuscular injection, 0.5 mg/day of Alfacalcidol was also administered	The progesterone group received 1 mg/kg of progesterone intramuscularly every 12 hours for 5 days, The progesterone-vitamin D group received 1 mg/kg of progesterone intramuscularly every 12 hours for 5 days and 5 µg/kg of vitamin D daily for 5 days. The placebo group received both placebos intravenously.	Patients in the intervention group were given a large dose of vitamin C and vitamin E based on the above routine treatment: 1st-4th day, Vitamin C 4.0 g, intravenous drip, 2 times a day; 5th-7th day, vitamin C 3.0 g, intravenous drip, 2 times a day; Vitamin E 100 mg, muscle injection, 1 time a day were given for the first 7 days.
Treatment 5 days Follow up day 5-28	Single injection 1 week and 3 months post-TBI follow-up	Five-days treatment 3-month follow-up	7-day treatment
The study protocol and results have not been published	1.1) Mean vitamin D level in 345 patients At admission were 13.62 ng/ml. There was no correlation between the initial vitamin D level and GOS-E in all TBI patients. During the first week, there was no significant variation in GOS-E score between the control and the supplement groups in all kinds of TBI severity. 2.1) However, at the three-month follow-up, the supplement group had a higher GOS-E score than the control group. The same results were achieved for the Mini-Mental Status Examination (MMSE) and Clinical Dementia Rating (CDR) score as cognitive outcomes. Patients with total TBI and mild-to-moderate TBI who received supplements exhibited greater functional recovery at the 3-month follow-up compared to the control group. Notably, the supplementation regimen did not impact the recovery rate, as measured by the GOS-E score, among patients with severe TBI. Serum levels of vitamin D significantly increased from 14.03 ng/mL at admission to 37.42 ng/mL at 3 months post-TBI in the supplement group(P<0.001). Thus, the increase in the Serum level of vitamin D was greater in the supplement group than in the control group (P <0.001). 2.2) Vitamin level changed from 13.57 ng/mL at admission to 16.77 ng/mL at 3 months post-TBI (P=0.021) in the control group.	2.1) 3 months after the intervention, there was a significant variation among the GCS means of the 3 groups with the dominance of progesterone-vitamin D group (P-value = 0.001). The recovery rate based on the GOS score in the progesterone-vitamin D group was higher than the other groups. There was a significant difference in mortality among the groups, with a lower rate in the progesterone-vitamin D group than in the other groups.	2.1) Analysis on the 3rd and 7th days post-treatment revealed that the intervention group exhibited significantly reduced levels of several biomarkers associated with nerve injury (NSE, S100B, NGB, UCH-L1), iron metabolism (Tf, Ft), and oxidative stress (NTF-κB, OH□, O□□, MDA, AOPP) compared to the control group. Conversely, the intervention group demonstrated significantly elevated serum concentrations of antioxidant enzymes (SOD, GPx, and CAT) at these time points. Administering high doses of vitamin C and vitamin E appears to be a therapeutic strategy for patients with acute craniocerebral injury, potentially mitigating nerve damage, reducing oxidative stress, and enhancing neurotrophic support.

Study protocol and results have not been published	Not mentioned	Not mentioned	Not mentioned,
Chemiluminescence method for measuring vitamin D instead of the gold standard technique, Potential blood transfusion and albumin injection in some patients interfere with the biochemistry test. The potential need for surgery other than brain surgery in patients, this factor could affect the study outcomes.	The supplement group was approximately three times larger than the control group. The control group had twice the number of patients involved in car accidents as drivers, which could negatively impact functional outcomes due to the diffuse nature of such injuries. The educational levels of the two groups differed, which could have affected cognitive outcomes. The exclusion of mortality cases, which accounted for a significant portion of severe TBI patients (40%), could have influenced the reported outcomes for the severe TBI and total TBI groups.	Small sample size Single-center study	None.

Table 3 *Meta-regression results for the influence of age and gender on GCS outcomes*

Covariate	No. of Studies	Estimate	Estimate SE	P Value	R^2	τ^2	I^2
Age	3	0.021	0.0544	0.701	0	0.094	44.258
Female	3	16.319	12.125	0.178	100	0	0

Farnoosh Masbough	**Sajjad Shafiei**
2024	2022
RCT	RCT
10.30476/ijms.2023.99465.3156.	http://dx.doi.org/10.32598/irjns.8.4
N: 35 (vitamin D3 level less than 30 ng/ml) Age 18-65 Intervention:19 F=1 M=18 Age M= 37.68±13.39 control groups:16 F= 3 M=13 Age M= 38.12±15.11	N: 84 intervention group (n=42) F=12 M=30 Age M= 36.76±16.12 control group (n=42) F=9 M=33 Age M= 41.92±16.79
between 3 to 12	GCS<13 Interventional group: 8.64±2.29 Placebo group: 8.42±2.93
Not mentioned.	Not mentioned.
The mean GCS in the vitamin D group was statistically increased (P=0.001).	Interventional group: 13.50±1.85 Placebo group: 10.97±2.37
a single IM dose of 300,000 IU of vitamin D3	oral single dose (150,000 units) of vitamin D and the placebo upon admission.
Single dose 3-month follow-up	Single dose 3-month follow-up
2.1) Analysis of GOS-E scores at three months revealed a statistically significant improvement in the vitamin D3 group compared to the control group (P=0.017) (five times more likely than the control group)	The GCS upon discharge significantly improved in both groups. 2.1) The mean GCS was significantly higher in the intervention group compared to the controls. The t-test indicated no significant differences between the intervention and control groups regarding the duration of mechanical ventilation (13.62±13.87 days vs. 16.42±12.33 days) and the mean length of hospital stay (19.37±13.24 days vs. 22.67±13.39 days).
Not mentioned.	Not mentioned.
single-center design	Small sample size

Figure 2. *Forest plot showing the standardized mean difference (SMD) in GCS scores between vitamin D-supplemented groups and control groups. A fixed-effect model was used due to low heterogeneity (I^2 = 0%).*

Discussion

Summary of Main Findings

In this systematic review and meta-analysis, the efficacy of vitamin D and vitamin E supplementation in patients with traumatic brain injury (TBI) was assessed across nine studies, including six randomized controlled trials and three cohort studies published between 2011 and 2024. Quantitative synthesis of three RCTs demonstrated a significant benefit of vitamin D on neurological recovery, with a pooled SMD of 1.02 (95% CI: 0.68–1.36, $p < 0.0001$) for GCS improvement, and negligible heterogeneity (I^2 = 0%). Functional recovery, as measured by the Glasgow Outcome Scale (GOS/GOS-E), also favored vitamin D and E supplementation, with multiple studies reporting higher rates of favorable outcomes and reduced mortality in the intervention groups. Both vitamins showed anti-inflammatory and antioxidant activity, reflected in reduced markers of oxidative stress and inflammatory cytokines.

Interpretation in the Context of Previous Research

The observed neurological improvement with vitamin D supplementation is consistent with findings from prior clinical and preclinical studies, which have suggested a role for vitamin D in modulating

neuroinflammation and promoting neurorecovery (17, 19-22). The anti-inflammatory cytokine profile following vitamin D administration—including reduced IL-6, TNF-α, and IL-2 with increased IFN-γ (20, 22)—may help attenuate the secondary injury cascade, supporting previous reports of its neuroprotective effects (4, 7, 22). Similarly, the positive impact of vitamin D on functional outcomes (as indicated by higher GOS/E scores) aligns with earlier evidence that adequate vitamin D status is associated with better post-TBI prognosis (17, 19).

Vitamin E demonstrated reductions in oxidative stress biomarkers (such as MDA, AOPP, NTF-κB) and neuronal injury markers (NSE, S100B), which concurs with its established antioxidative mechanisms (10, 11, 25). The observed decrease in mortality in vitamin E groups (24) supports the hypothesis that antioxidant therapy may confer survival benefits in severe TBI, as previously reported in related translational studies (11).

Of note, adjunctive treatment with vitamin D and progesterone was associated with lower mortality compared to progesterone alone or placebo (18), suggesting potential synergistic effects, as also noted in experimental models (14, 26). However, not all studies reported significant improvements in all outcomes, and variations in dosing, timing, and study population characteristics likely contributed to heterogeneity.

Clinical Implications

The present findings highlight the potential role of vitamin D supplementation—and to a lesser extent vitamin E—in improving neurological recovery and reducing complications following moderate-to-severe TBI. Considering the low risk profile and high prevalence of vitamin D deficiency among critically ill patients, routine screening and early correction may be considered as part of neurocritical care protocols (17, 22). Nevertheless, current evidence does not yet support universal high-dose vitamin supplementation for all TBI patients; further individualized assessment remains necessary.

Limitations

Several limitations must be noted. The total number of high-quality randomized controlled trials remains limited, with only three studies comprising the meta-analysis of GCS outcomes. Sample sizes were small in several studies, reducing statistical power. There was heterogeneity in vitamin dosing regimens (ranging from 50,000 to 300,000 IU for vitamin D), modes of administration (oral, intramuscular, intravenous), and follow-up durations (most limited to three months or less). Some studies combined vitamin supplementation with other interventions (e.g., progesterone), complicating attribution of effects.

Risk of bias was generally low, but some studies had issues related to incomplete blinding or outcome reporting. Finally, publication bias cannot be entirely excluded, despite negative findings on formal testing (Egger's test, funnel plot).

Future Directions and Conclusion

Larger, multicenter RCTs with standardized vitamin supplementation protocols, longer follow-up, and consistent outcome definitions are required to validate these findings and clarify long-term benefits. Research should also explore the potential for combination therapies (e.g., vitamin D with progesterone) and optimal patient selection.

In summary, evidence supports a beneficial effect of vitamin D—and possibly vitamin E—on early neurological recovery and some clinical outcomes following moderate-to-severe TBI, though routine use awaits confirmation in further high-quality studies.

Conclusion:

This systematic review and meta-analysis provide moderate-quality evidence that vitamin D supplementation, and possibly vitamin E, confer measurable benefits on early neurological recovery and selected clinical outcomes in patients with moderate-to-severe traumatic brain injury. Despite statistically significant improvements—particularly in Glasgow Coma Scale scores—across available randomized trials, the current evidence base is restricted by methodological heterogeneity, limited sample sizes, and predominantly short-term follow-up. Accordingly, while routine correction of vitamin D deficiency may be justified as part of comprehensive neurocritical care, universal high-dose supplementation cannot yet be broadly recommended. Further large-scale, rigorously designed clinical trials are warranted to clarify optimal dosing strategies, long-term efficacy, and potential synergistic effects with other neuroprotective agents.

Declarations

Ethical approval and consent to participate:

Not applicable

Consent for publication:

All authors approve this statement

Availability of data and materials:

Not applicable

Competing interests: The authors have no competing interests.

Funding:

This study did not receive any financial support.

Author contributions

Conceptualization: F.V, Data curation: H.Y, M.M, Formal analysis: M.M, A.Z, Investigation: I.S, T.E, K.M Methodology: K.M, A.B, Project administration: F.F, Writing – original draft: M.M, Sh.M, Sh.N, S.O, Writing – review and editing: F.V, A.Z.

Acknowledgements:

Not applicable

Preprint:

https://doi.org/10.1101/2025.10.07.25337269

References

1. Dewan MC, Rattani A, Gupta S, Baticulon RE, Hung YC, Punchak M, et al. Estimating the global incidence of traumatic brain injury. Journal of neurosurgery. 2019;130(4):1080-97.
2. Guan B, Anderson DB, Chen L, Feng S, Zhou H. Global, regional and national burden of traumatic brain injury and spinal cord injury, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. BMJ open. 2023;13(10):e075049.
3. Basak D, Chatterjee S, Attergrim J, Sharma MR, Soni KD, Verma S, et al. Glasgow coma scale compared to other trauma scores in discriminating in-hospital mortality of traumatic brain injury patients admitted to urban Indian hospitals: A multicentre prospective cohort study. Injury. 2023;54(1):93-9.

4. Lozano D, Gonzales-Portillo GS, Acosta S, de la Pena I, Tajiri N, Kaneko Y, et al. Neuroinflammatory responses to traumatic brain injury: etiology, clinical consequences, and therapeutic opportunities. Neuropsychiatric disease and treatment. 2015;11:97-106.
5. Werner C, Engelhard K. Pathophysiology of traumatic brain injury. British journal of anaesthesia. 2007;99(1):4-9.
6. Morganti-Kossmann MC, Satgunaseelan L, Bye N, Kossmann T. Modulation of immune response by head injury. Injury. 2007;38(12):1392-400.
7. Woodcock T, Morganti-Kossmann MC. The role of markers of inflammation in traumatic brain injury. Frontiers in neurology. 2013;4:18.
8. Alexander MP. Mild traumatic brain injury: pathophysiology, natural history, and clinical management. Neurology. 1995;45(7):1253-60.
9. Bratton SL, Chestnut RM, Ghajar J, McConnell Hammond FF, Harris OA, Hartl R, et al. Guidelines for the management of severe traumatic brain injury. IX. Cerebral perfusion thresholds. Journal of neurotrauma. 2007;24 Suppl 1:S59-64.
10. Cao W, Carney JM, Duchon A, Floyd RA, Chevion M. Oxygen free radical involvement in ischemia and reperfusion injury to brain. Neuroscience letters. 1988;88(2):233-8.
11. Hall ED, Vaishnav RA, Mustafa AG. Antioxidant therapies for traumatic brain injury. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2010;7(1):51-61.
12. Tan Q, Wang Y, Zhang G, Lu B, Wang T, Tao T, et al. The metabolic effects of multi-trace elements on parenteral nutrition for critically ill pediatric patients: a randomized controlled trial and metabolomic research. Translational pediatrics. 2021;10(10):2579-93.
13. Lin AM, Fan SF, Yang DM, Hsu LL, Yang CH. Zinc-induced apoptosis in substantia nigra of rat brain: neuroprotection by vitamin D3. Free radical biology & medicine. 2003;34(11):1416-25.
14. Tang H, Hua F, Wang J, Yousuf S, Atif F, Sayeed I, et al. Progesterone and vitamin D combination therapy modulates inflammatory response after traumatic brain injury. Brain injury. 2015;29(10):1165-74.
15. Aiguo W, Zhe Y, Gomez-Pinilla F. Vitamin E protects against oxidative damage and learning disability after mild traumatic brain injury in rats. Neurorehabilitation and neural repair. 2010;24(3):290-8.
16. Chen G, Shi J, Qi M, Yin H, Hang C. Glutamine decreases intestinal nuclear factor kappa B activity and pro-inflammatory cytokine expression after traumatic brain injury in rats. Inflammation research : official journal of the European Histamine Research Society [et al]. 2008;57(2):57-64.
17. Guan J, Karsy M, Brock AA, Eli IM, Manton GM, Ledyard HK, et al. Vitamin D status and 3-month Glasgow Outcome Scale scores in patients in neurocritical care: prospective analysis of 497 patients. Journal of neurosurgery. 2018;128(6):1635-41.
18. Aminmansour B, Nikbakht H, Ghorbani A, Rezvani M, Rahmani P, Torkashvand M, et al. Comparison of the administration of progesterone versus progesterone and vitamin D in improvement of outcomes in patients with traumatic brain injury: A randomized clinical trial with placebo group. Advanced biomedical research. 2012;1:58.

19. Lee JM, Jeong SW, Kim MY, Park JB, Kim MS. The Effect of Vitamin D Supplementation in Patients with Acute Traumatic Brain Injury. World neurosurgery. 2019;126:e1421-e6.
20. Masbough F, Kouchek M, Koosha M, Salarian S, Miri M, Raoufi M, et al. Investigating the Effect of High-Dose Vitamin D3 Administration on Inflammatory Biomarkers in Patients with Moderate to Severe Traumatic Brain Injury: A Randomized Clinical Trial. Iranian journal of medical sciences. 2024;49(10):643-51.
21. Shafiei S, Zaheriani MS, Sahfizad M, Ehteshami S, Mosazadeh M, Haddadi K. Neuroprotective Effects of Vitamin D on Patients With Traumatic Brain Injury: A Clinical Trial. IrJNS. 2022;8(1):4

EP.
22. Sharma S, Kumar A, Choudhary A, Sharma S, Khurana L, Sharma N, et al. Neuroprotective Role of Oral Vitamin D Supplementation on Consciousness and Inflammatory Biomarkers in Determining Severity Outcome in Acute Traumatic Brain Injury Patients: A Double-Blind Randomized Clinical Trial. Clinical drug investigation. 2020;40(4):327-34.
23. Inci S, Ozcan OE, Kilinç K. Time-level relationship for lipid peroxidation and the protective effect of alpha-tocopherol in experimental mild and severe brain injury. Neurosurgery. 1998;43(2):330-5; discussion 5-6.
24. Razmkon A, Sadidi A, Sherafat-Kazemzadeh E, Mehrafshan A, Jamali M, Malekpour B, et al. Administration of vitamin C and vitamin E in severe head injury: a randomized double-blind controlled trial. Clinical neurosurgery. 2011;58:133-7.
25. Zhang C, Li J-M, Hu J-L, Zhou X. The effects of large doses of vitamin C and vitamin E on nerve injury, neurotrophic and oxidative stress in patients with acute craniocerebral injury. Journal of Acute Disease. 2018;7(2).
26. Cekic M, Sayeed I, Stein DG. Combination treatment with progesterone and vitamin D hormone may be more effective than monotherapy for nervous system injury and disease. Frontiers in neuroendocrinology. 2009;30(2):158-72.